Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,382 | 171 | 69.8% |
| Long term medical supply or device loan | $1,196 | 12 | 24.7% |
| Education | $165.56 | 5 | 3.4% |
| Consulting Fee | $100.00 | 1 | 2.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,583 | 35 | $0 (2024) |
| Janssen Biotech, Inc. | $322.20 | 15 | $0 (2024) |
| PFIZER INC. | $233.26 | 14 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $212.20 | 15 | $0 (2021) |
| ABBVIE INC. | $202.32 | 8 | $0 (2024) |
| Genentech USA, Inc. | $194.21 | 5 | $0 (2022) |
| Seagen Inc. | $162.87 | 4 | $0 (2023) |
| Amgen Inc. | $156.33 | 9 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $145.73 | 8 | $0 (2024) |
| Celgene Corporation | $134.71 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,195 | 49 | Novartis Pharmaceuticals Corporation ($1,231) |
| 2023 | $368.35 | 14 | Seagen Inc. ($146.28) |
| 2022 | $346.38 | 17 | EISAI INC. ($66.17) |
| 2021 | $108.22 | 6 | PFIZER INC. ($44.60) |
| 2020 | $65.55 | 4 | Novartis Pharmaceuticals Corporation ($21.12) |
| 2019 | $508.84 | 30 | Novartis Pharmaceuticals Corporation ($119.72) |
| 2018 | $725.72 | 34 | Genentech USA, Inc. ($147.38) |
| 2017 | $525.64 | 35 | Janssen Biotech, Inc. ($79.77) |
All Payment Transactions
189 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $21.07 | General |
| Category: Oncology | ||||||
| 12/12/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Education | In-kind items and services | $13.04 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Education | In-kind items and services | $96.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/11/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $44.08 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/29/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $49.88 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 09/12/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/04/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: ONCOLOGY | ||||||
| 09/03/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $25.27 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $28.55 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 08/22/2024 | GENZYME CORPORATION | CABLIVI (Biological) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Hematology | ||||||
| 08/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: Oncology | ||||||
| 08/07/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Oncology | ||||||
| 07/31/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $27.86 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: Oncology | ||||||
| 07/15/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 06/27/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $25.82 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 409 | 543 | $174,864 | $46,321 |
| 2022 | 5 | 359 | 473 | $128,583 | $39,943 |
| 2021 | 8 | 377 | 476 | $130,675 | $47,942 |
| 2020 | 8 | 373 | 554 | $124,534 | $36,068 |
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 185 | 278 | $78,381 | $19,074 | 24.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 84 | 124 | $47,865 | $13,481 | 28.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 47 | 47 | $22,727 | $6,652 | 29.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $11,623 | $3,314 | 28.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 25 | 25 | $6,725 | $1,944 | 28.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 37 | 38 | $7,543 | $1,856 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 173 | 253 | $58,960 | $17,798 | 30.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 90 | 123 | $38,421 | $13,012 | 33.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 45 | 45 | $19,033 | $5,349 | 28.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 22 | 22 | $7,372 | $2,393 | 32.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 29 | 30 | $4,797 | $1,391 | 29.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 117 | 180 | $51,840 | $20,449 | 39.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 126 | 156 | $33,540 | $11,374 | 33.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 55 | 55 | $22,550 | $7,819 | 34.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 15 | $5,955 | $2,429 | 40.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 20 | 20 | $6,620 | $1,999 | 30.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 19 | 24 | $4,872 | $1,921 | 39.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 12 | 12 | $3,240 | $1,236 | 38.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 13 | 14 | $2,058 | $715.00 | 34.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 150 | 284 | $61,060 | $16,304 | 26.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 82 | 111 | $16,317 | $4,152 | 25.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 38 | 38 | $12,578 | $3,374 | 26.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 28 | 35 | $10,080 | $2,972 | 29.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 24 | 35 | $7,105 | $2,930 | 41.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 24 | 24 | $6,480 | $2,421 | 37.4% |
About Dr. Madhurima Uppalapati, MD
Dr. Madhurima Uppalapati, MD is a Hematology & Oncology healthcare provider based in Marietta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497711931.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Madhurima Uppalapati, MD has received a total of $4,844 in payments from pharmaceutical and medical device companies, with $2,195 received in 2024. These payments were reported across 189 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($3,382).
As a Medicare-enrolled provider, Uppalapati has provided services to 1,518 Medicare beneficiaries, totaling 2,046 services with total Medicare billing of $170,274. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Marietta, GA
- Active Since 04/25/2006
- Last Updated 06/10/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1497711931
Products in Payments
- KISQALI (Drug) $1,377
- IMBRUVICA (Drug) $204.71
- IBRANCE (Drug) $160.74
- Avastin (Biological) $135.76
- EPKINLY (Drug) $133.55
- TUKYSA (Drug) $131.73
- DARZALEX (Biological) $123.35
- XTANDI (Drug) $113.52
- ADCETRIS (Biological) $110.16
- Lenvima (Drug) $109.35
- Enhertu (Drug) $90.64
- SOMATULINE DEPOT (Drug) $90.23
- Kerendia (Drug) $84.81
- OPDIVO (Biological) $80.34
- MEKINIST (Drug) $70.20
- ENHERTU (Biological) $68.39
- EMPLICITI (Biological) $67.91
- DOPTELET (Drug) $65.36
- PIQRAY (Drug) $57.00
- Neulasta (Biological) $54.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Marietta
Dr. Steven Mccune, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $492,856
Dr. Gena Volas-Redd, Md, MD
Hematology & Oncology — Payments: $115,709
Dr. John French, Md, MD
Hematology & Oncology — Payments: $70,611
Dr. Louis Garrot, M.d, M.D
Hematology & Oncology — Payments: $57,738
Vivek Abhyankar, Md, MD
Hematology & Oncology — Payments: $53,680
Dr. Dean Kirkel, Md, MD
Hematology & Oncology — Payments: $53,593